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G protein-coupled receptor kinase 2 (GRK2) phosphorylates
activated G protein-coupled receptors (GPCRs), which ultimately
leads to their desensitization and/or downregulation. The enzyme is
recruited to the plasma membrane via the interaction of its carboxyl-
terminal pleckstrin-homology (PH) domain with the  and  subunits
of heterotrimeric G proteins (G). An improved puri®cation
scheme for GRK2 has been developed, conditions under which
GRK2 forms a complex with G12 have been determined and the
complex has been crystallized in CHAPS detergent micelles. Crystals
of the GRK2±G complex belong to space group C2 and have unit-
cell parameters a = 187.0, b = 72.1, c = 122.0 AÊ , = 115.2. A complete
data set has been collected to 3.2 AÊ resolution with Cu K radiation.
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1. Introduction
G-protein coupled receptors (GPCRs) are
responsible for many signaling processes,
including the regulation of heart rate and
blood pressure and the sensations of sight,
smell and taste (Pitcher et al., 1998). G protein-
coupled receptor kinases (GRKs) play a key
role in the desensitization of GPCR signaling
by phosphorylating the cytoplasmic loops or
tails of activated receptors. Subsequently,
arrestins bind to these phosphorylated loops
and uncouple the receptors from hetero-
trimeric G proteins (Sterne-Marr & Benovic,
1995). GRK2 (previously referred to as
-adrenergic receptor kinase 1) is a ubiquitous
enzyme that can phosphorylate many GPCRs,
including cardiac adrenergic receptors (Pitcher
et al., 1999). Its physiological roles in the heart
include the regulation of heart rate and the
proper development of cardiac tissue (Jaber et
al., 1996). However, abnormally high GRK2
activity has been implicated in a variety of
disorders including chronic heart failure and
myocardial ischemia (Ungerer et al., 1996).
Inhibitors of GRK2 therefore hold great
promise for the treatment of cardiovascular
disease (Iaccarino et al., 1999).
GRK2 is an 80 kDa protein that consists of
three domains: an amino-terminal regulator of
G-protein signaling (RGS) homology (RH)
domain, a central kinase domain and a
carboxyl-terminal pleckstrin-homology (PH)
domain (Benovic et al., 1986). GRK2 activity is
stimulated by the interaction of its PH domain
with G subunits (Pitcher et al., 1992) and
anionic phospholipids (Pitcher et al., 1996;
DebBurman et al., 1996). These interactions
help to recruit GRK2 to the plasma membrane
near activated GPCRs. Many other important
effector enzymes have PH domains that
interact with G subunits, including Bruton's
tyrosine kinase (Tsukada et al., 1994) and
phospholipase C (Wang et al., 1999). The
molecular basis for the interaction between PH
domains and G is not known.
The crystal structure of the GRK2±G
complex will reveal not only the common
molecular architecture of all GRKs, but also
how G interacts with the PH domain of a
bona ®de effector target. The structure will also
provide a model for how three modular
signaling domains can successfully integrate
their individual activities within a single poly-
peptide chain. Towards this end, we have
developed an improved and ef®cient puri®ca-
tion scheme for GRK2 and determined
conditions under which GRK2 forms a 1:1
complex with prenylated G in detergent
micelles. We have crystallized this complex and
collected a preliminary data set to 3.2 AÊ reso-
lution on a home X-ray source.
2. Methods
2.1. Purification of GRK2
Bovine GRK2 and bovine G12 were co-
expressed in Sf9 insect cells using the baculo-
virus expression system. Co-expression was
used to enhance the expression levels of both
G and GRK2, but was not exploited to
isolate the complex. A volume of 8 l (16 
500 ml) of Sf9 cells in log phase was co-infected
with baculoviruses containing genes for
GRK2(S670A), wild-type G1 and a mutant
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G2 engineered to have an amino-terminal
hexahistidine (H6) tag. The S670A mutation
of GRK2 removes a MAP kinase phos-
phorylation site that results in hetero-
geneously phosphorylated preparations of
wild-type GRK2 (Pitcher et al., 1999). The
multiplicity of infection (MOI) for all viruses
was between 5 and 10. The infected cells
were allowed to grow for 48 h, then pelleted
(2500g for 15 min) and resuspended in
80 ml of ice-cold 10 mM HEPES pH 7.2,
100 mM NaCl, 5 mM EDTA containing
protease inhibitors (1 mM PMSF, 1 mM
benzamidine, 1 mM leupeptin and 1 mM
pepstatin A). This solution was ¯ash-frozen
in liquid nitrogen and stored at 193 K. The
cells were thawed in a 310 K water bath and
resuspended in a total volume of 200 ml
buffer A (20 mM HEPES pH 8.0, 50 mM
NaCl, 2.5 mM EDTA, 2 mM DTT)
containing protease inhibitors (1 mM
leupeptin, 1 mM lima bean trypsin inhibitor,
1 mM PMSF and 1 mM TPCK). All subse-
quent steps of the puri®cation were
performed at 277 K. The cells were lysed
with a dounce homogenizer and then
subjected to ultracentrifugation at 186 000g
for 40 min (40 000 rev minÿ1 in a Beckman
Ti-45 rotor). The supernatant and cell pellets
were reserved. Cell pellets were resus-
pended with a Vertishear tissue homo-
genizer (VirTis) in 100 ml of buffer A,
dounced a second time and subjected to a
second round of ultracentrifugation. The
supernatants from the two ultracentrifuga-
tion runs were pooled for the puri®cation of
GRK2 and the cell pellets were saved for the
subsequent puri®cation of G.
GRK2 was subsequently puri®ed using
three successive cation-exchange steps. The
pooled ultracentrifugation supernatant was
applied at 3 ml minÿ1 to a 25 ml Macroprep
High S support column (Bio-Rad) using a
25 ml Macroprep DEAE column (Bio-Rad)
as a pre-®lter. The DEAE column was then
removed and GRK2 was eluted from the
High S column with a 50±500 mM NaCl
gradient in buffer B (20 mM HEPES
pH 8.0 and 1 mM dithiothreitol). Fractions
containing GRK2 were identi®ed using
SDS±PAGE, pooled and diluted to a ®nal
NaCl concentration of 50 mM. The resulting
mixture was loaded onto a 35 ml FF heparin
Sepharose column (Amersham Pharmacia
Biotech) and eluted with a 50±500 mM NaCl
gradient in buffer B. GRK2 fractions were
pooled, diluted to 50 mM NaCl, loaded onto
an 8 ml Source 15 S column (Amersham
Pharmacia Biotech) and eluted with a
50±300 mM NaCl gradient in buffer B.
Pooled fractions of GRK2 were concen-
trated to 5 ml and puri®ed on a 16/60
Superdex S200 preparative gel-
®ltration column (Amersham
Pharmacia Biotech) pre-equili-
brated in a buffer containing
20 mM HEPES pH 8.0, 200 mM
NaCl and 2 mM DTT. Fractions
containing GRK2 were then
concentrated using a 50 kDa
Centriprep (Millipore) to at least
10 mg mlÿ1 and frozen as 50 ml
pellets in liquid nitrogen. The
typical yield from 8 l of Sf9 cell
culture varied from 40 to 200 mg
of near-homogenous GRK2.
2.2. Purification of Gb1c2
G12 subunits were puri®ed
from the membrane-containing
Sf9 cell pellets as previously
described (Kozasa, 1999) with
some modi®cations. Brie¯y, the
cell pellets were resuspended in
1% sodium cholate (Sigma) to
solubilize membrane proteins.
The G subunits were then
bound to a 4 ml Ni±NTA column
(Qiagen) by virtue of the H6 tag
on G2 and the column was
treated with GDP and AlF3 to
activate and release endogenous
G subunits. G was then
eluted with 200 mM imidazole
and further puri®ed using a 1 ml
Mono Q column (from Amer-
sham Pharmacia Biotech).
Finally, G was puri®ed by gel-
®ltration chromatography on
two Pharmacia 10/30 Superdex
200 columns connected in
tandem that had been pre-equilibrated with
a buffer containing 20 mM HEPES,
100 mM NaCl, 10 mM 3-[(3-cholamido-
propyl) dimethylammonio]-1-propanesulfo-
nate (CHAPS) and 1 mM DTT. G was
concentrated to at least 7 mg mlÿ1 and
frozen as 50 ml pellets in liquid nitrogen. The
typical yield of G from membranes
isolated from 8 l of cell culture varied from 6
to 16 mg.
2.3. Reconstitution and purification of the
GRK2±Gbc complex
GRK2 (80 kDa) was mixed with excess
G (45 kDa) in order to facilitate separa-
tion of their complex from uncomplexed
proteins by gel-®ltration chromatography.
GRK2 and G concentrations were deter-
mined by the Bradford assay and the
proteins were then mixed together in a mass
ratio of 0.85 (a 2:3 molar ratio of
GRK2:G) in a buffer containing 20 mM
Figure 1
Puri®cation of the GRK2±G complex. (a) Separation of the
GRK2±G complex from excess G using two tandem Superdex
200 gel-®ltration columns. The molecular weights listed at the top of
the chromatogram correspond to the molecular weights of gel-
®ltration standards (Bio-Rad) eluted under the same conditions.
(b) SDS±PAGE analysis of fractions eluted from the gel-®ltration
column. The leftmost lane contains Bio-Rad Precision protein
standards.
Figure 2
Crystal of the GRK2± complex. Crystals of the
GRK2±G complex nucleate over the course of 10±
20 d at 277 K and reach maximum dimensions
(typically 350  150  50 mm) after one month.
Crystals are shaped like thin diamonds, with the
350 mm and 150 mm lengths corresponding to the long
and short axes of the diamond, respectively. The
crystal shown has dimensions 300 100 50 mm and
belongs to space group C2 (a = 187.0, b = 72.1,
c = 122.0,  = 115.2).
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HEPES pH 8.0, 100 mM NaCl, 10 mM
CHAPS, 5 mM ATP, 10 mM MgCl2 and
1 mM DTT. After incubation on ice for 1 h,
the GRK2±G complex was injected onto
two 10/30 Superdex 200 columns in tandem
that had been pre-equilibrated with 20 mM
HEPES pH 8.0, 100 mM NaCl, 10 mM
CHAPS, 1 mM ATP, 5 mM MgCl2 and 2 mM
DTT (Fig. 1). Compared with gel-®ltration
standards (Bio-Rad), the GRK2/G/
detergent micelle mixture eluted in two
peaks with effective molecular weights of
180 and 70 kDa (Fig. 1a). The 180 kDa peak
was consistent with a 1:1 complex between
GRK2 and G bound to a CHAPS deter-
gent micelle and the 70 kDa peak to a G±
CHAPS detergent micelle complex. GRK2
eluted from the same gel-®ltration columns
with an effective molecular weight of
90 kDa. SDS±PAGE analysis corroborated
these assignments (Fig. 1b). Omission of
ATP in the running buffer delayed the
elution time of the GRK2±G complex,
indicating that the complex loses af®nity in
the absence of ATP. Crystals grown from
protein thus puri®ed were also much smaller
in size and ill-formed compared with those
grown in the presence of ATP. Peak frac-
tions of the complex were pooled, concen-
trated to 12 mg mlÿ1 and frozen as 50 ml
pellets in liquid nitrogen. Excess G was
saved from multiple runs, concentrated and
recycled for use in future reconstitutions.
We have also formed complexes between
G and the independently expressed
GRK2 PH domain using the C68S mutant of
G2 (Koch et al., 1993), which eliminates its
isoprenylation site and renders G soluble.
The PH±G complexes do not require
detergent micelles to form and can be
readily puri®ed by gel-®ltration chromato-
graphy, but to date have not yielded crystals.
Surprisingly, full-length GRK2 fails to form
a complex with G12C68S that can be
isolated by gel-®ltration chromatography.
2.4. Crystallization
Small plate-like crystals of GRK2±G
complex were initially observed in a two-
dimensional hanging-drop screen using PEG
3350 (5±20%) versus pH (5±7.5) as the
variable parameters. All wells also contained
1 M NaCl. The best quality crystals grow
from hanging drops containing 1 ml complex
at 12 mg mlÿ1 and 1 ml of a well solution
containing 100 mM MES pH 5.25, 200 mM
NaCl, 1 mM inositol-3,4,5-triphosphate
(IP3), 5 mM MgCl2 and 6.9±7.8% PEG 3350
suspended over 1 ml of the well solution. IP3
is included as a soluble mimic of the head
group of PIP2, a regulator of GRK2 (Pitcher
et al., 1996; DebBurman et al., 1996) (Fig. 2).
SDS±PAGE analysis of protein recovered
from crystals indicates that both GRK2 and
G are present in the crystals (data not
shown).
Crystals of the GRK2±G complex also
grow in the presence of 10 mM EDTA,
which should effectively inhibit the binding
of ATP, in the absence of IP3 and in the
presence of phosphatidylserine. These crys-
tals diffract similarly to those described
above and have nearly identical unit-cell
parameters. Either these compounds are not
bound to the crystallized form of GRK2 or
they do not provoke a large conformational
change when they bind.
2.5. X-ray diffraction data collection and
processing
Crystals were equilibrated in a cryo-
protectant solution containing 25% ethylene
glycol, 8% PEG 3350, 20 mM HEPES
pH 8.0, 100 mM MES pH 5.25, 300 mM
NaCl, 1 mM DTT, 2 mM MgCl2, 1 mM IP3,
1 mM ATP and 10 mM CHAPS by gradually
adding cryoprotectant to the hanging drop
in 0.5 ml aliquots. Crystals were then trans-
ferred to a 100% cryoprotectant solution
using an appropriately sized cryoloop
(Hampton Research) and allowed to equi-
librate for 5±10 min. The crystals were then
suspended in a cryoloop and frozen in liquid
nitrogen or a nitrogen cold stream.
A complete data set (346 frames with
30 min 0.5 oscillations totalling 173) was
collected with a Rigaku RU-200H Cu K
X-ray source using Osmic confocal mirrors
and a MAR345 imaging-plate system. A
cold stream from an Oxford Instruments
Cryojet maintained the temperature of the
crystal at 90 K. The GRK2±G complex
crystals belonged to space group C2, with
unit-cell parameters a = 187.0, b = 72.1,
c = 122.0 AÊ , = 115.2 (Table 1). The crystals
have a Matthews coef®cient (VM) of
2.5 AÊ 3 Daÿ1 (Matthews, 1968), suggesting
that only one complex is found in each
asymmetric unit. Longer 0.5 exposures for
1 h yield higher resolution diffraction, indi-
cating that a synchrotron source would allow
collection of superior data. The data were
reduced and scaled together using the HKL
package (Otwinowski & Minor, 1997).
Analysis using TRUNCATE (Collaborative
Computational Project, Number 4, 1994)
indicated that the diffraction intensities are
severely anisotropic, with the highest reso-
lution data extending in a direction nearly
bisecting the a* and c* axes and the weakest
extending along the b* axis. This anisotropy
obscures the presence of well measured
re¯ections in the highest resolution shells
(Table 1). A preliminary molecular-replace-
ment solution using the crystal structures of
G12 (Wall et al., 1995) and the homo-
logous kinase domain of protein kinase A
(Smith et al., 1999) as search models has
unambiguously located both G and the
kinase domain of GRK2 within the unit cell.
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